TDA you can bet your bottom dollar if PAT-SM6 improves Kyprolis in combination they will swoop either the drug or the entire company. Kyprolis is Onyx flagship drug & the main target Amgen was fighting for in its takeover - they are not going to let it slip past if it raises the standing of Kyprolis. Another thing here Onyx / Amgen are trying to get the drug into Europe and what better way than to partner it with SM6 already granted orphan designation by the EMA.
temptation, page-9
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 4291214 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 600160 | 2 |
View Market Depth
| Last trade - 16.12pm 09/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable